{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:38:15Z","timestamp":1774341495975,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.dld.2022.10.002","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T07:43:45Z","timestamp":1666424625000},"page":"1034-1041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-8451","authenticated-orcid":false,"given":"Lauranne A.A.P.","family":"Derikx","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolas","family":"Plevris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanna","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Gros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros I.","family":"Siakavellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Constantine-Cooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"O'Hare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Noble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian D.","family":"Arnott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth-Rhys","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie W","family":"Lees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.dld.2022.10.002_bib0001","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.dld.2022.10.002_bib0002","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2022.10.002_bib0003","article-title":"Effectiveness and safety of ustekinumab intensification at 90 Mg every four weeks in Crohn's disease: a multicenter study","author":"Fumery","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.dld.2022.10.002_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"10342","key":"10.1016\/j.dld.2022.10.002_bib0005","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.dld.2022.10.002_bib0006","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/ibd\/izy320","article-title":"Higher adalimumab drug levels during maintenance therapy for Crohn's disease are associated with biologic remission","volume":"25","author":"Plevris","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.dld.2022.10.002_bib0007","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2022.10.002_bib0008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J Crohn's Colitis"},{"issue":"8","key":"10.1016\/j.dld.2022.10.002_bib0009","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/apt.15484","article-title":"Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases","volume":"50","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2022.10.002_bib0010","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.dld.2022.10.002_bib0011","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ibd\/izaa282","article-title":"Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification","volume":"27","author":"Dalal","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2022.10.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820959245","article-title":"Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease","volume":"13","author":"Haider","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"10.1016\/j.dld.2022.10.002_bib0013","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/apt.15784","article-title":"Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy","volume":"52","author":"Kopylov","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dld.2022.10.002_bib0014","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cgh.2020.02.035","article-title":"Effectiveness of ustekinumab dose escalation in patients with Crohn's disease","volume":"19","author":"Ollech","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"21","key":"10.1016\/j.dld.2022.10.002_bib0015","article-title":"Effectiveness of re-induction and\/or dose escalation of ustekinumab in Crohn\u2019s disease: a systematic review and meta-analysis","volume":"S1542-3565","author":"Meserve","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2022.10.002_bib0016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/apt.15745","article-title":"Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment","volume":"52","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.10.002_bib0017","unstructured":"https:\/\/www.nrscotland.gov.uk\/statistics-and-data\/statistics\/statistics-by-theme\/population\/population-estimates\/mid-year-population-estimates\/population-estimates-time-series-data."},{"issue":"11","key":"10.1016\/j.dld.2022.10.002_bib0018","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1136\/gutjnl-2019-318936","article-title":"IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology","volume":"68","author":"Jones","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.dld.2022.10.002_bib0019","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/apt.16867","article-title":"Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis","volume":"56","author":"Lyons","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.dld.2022.10.002_bib0020","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/ecco-jcc\/jjw087","article-title":"Clinical Outcomes Following a Switch from Remicade\u00ae to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: a Prospective Observational Cohort Study","volume":"10","author":"Smits","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.dld.2022.10.002_bib0021","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2022.10.002_bib0022","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"7","key":"10.1016\/j.dld.2022.10.002_bib0023","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/apt.16802","article-title":"Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases","volume":"55","author":"Yang","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.10.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izab357","article-title":"Long-term real-world effectiveness and safety of ustekinumab in Crohn's disease patients: the SUSTAIN study","author":"Chaparro","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.dld.2022.10.002_bib0025","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/MIB.0000000000000842","article-title":"Ustekinumab for the treatment of refractory Crohn's disease: the Spanish experience in a large multicentre open-label cohort","volume":"22","author":"Khorrami","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.dld.2022.10.002_bib0026","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MIB.0000000000001074","article-title":"Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn's disease: real-world experience from a multicenter cohort study","volume":"23","author":"Ma","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.dld.2022.10.002_bib0027","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/apt.14487","article-title":"Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience","volume":"47","author":"Wils","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.10.002_bib0028","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara."},{"issue":"4","key":"10.1016\/j.dld.2022.10.002_bib0029","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","article-title":"Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.dld.2022.10.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease","volume":"15","author":"Battat","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.dld.2022.10.002_bib0031","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/apt.16785","article-title":"Review article: emerging drug therapies in inflammatory bowel disease","volume":"55","author":"Grossberg","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dld.2022.10.002_bib0032","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1053\/j.gastro.2021.06.040","article-title":"775d Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn's disease: the SEAVUE study","volume":"161","author":"Sands","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822007344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822007344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:22:12Z","timestamp":1761625332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865822007344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1590865822007344"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2022.10.002","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2022.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}